Annals of the Rheumatic Diseases

Declining in-hospital mortality gap between systemic lupus erythematosus (SLE) and non-SLE hospitalisations: A national study.  80:672-675. 2021

Burden and trajectory of multimorbidity in rheumatoid arthritis: A matched cohort study from 2006 to 2015.  80:286-292. 2021

SARS CoV-2 infection among patients using immunomodulatory therapies.  80:269-271. 2021

Circulating microbial small RNAs are altered in patients with rheumatoid arthritis.  79:1557-1564. 2020

Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data.  79:1400-1413. 2020

Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: Data from the COVID-19 Global Rheumatology Alliance physician-reported registry.  79:859-866. 2020

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update.  79:S685-S699. 2020

Immunosuppression and the risk of readmission and mortality in patients with rheumatoid arthritis undergoing hip fracture, abdominopelvic and cardiac surgery.  79:573. 2020

Hypersensitivity reactions with allopurinol and febuxostat: A study using the Medicare claims data.  79:529-535. 2020

Allopurinol versus febuxostat hypersensitivity reactions in the US elderly: Differences in study outcomes and populations. Response to: 'Correspondence to "hypersensitivity reactions with allopurinol and febuxostat: A study using the Medicare claims data' by Ma et al 2020

Hypersensitivity reactions with allopurinol versus febuxostat in the US elderly. Response to: 'Confunding by indication and ethnicity difference? Comment on 'Hypersensitivity reactions with allopurinol and febuxostat: A study using the Medicare claims data'' by Hsu et al 2020

Response to: Â &tild; Successful treatment of plasma exchange for refractory systemic juvenile idiopathic arthritis complicated with macrophage activation syndrome and severe lung disease' by Sato et al 2020

Response to: € Cutaneous adverse events with febuxostat after previous reactions to allopurinol: Comment on the artcile by Singh and Clevland' by Quills et al 2020

Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions of disease states of gout.  78:1592-1600. 2019

Response to: 'Clinical evidence guidelines in systemic lupus erythematosus: revaluation' by Scheinberg.  78. 2019

Association of response to TNF inhibitors in rheumatoid arthritis with quantitative trait loci for CD40 and CD39.  78:1055-1061. 2019

Gout is associated with increased healthcare utilization after knee arthroplasty.  78:1146-1148. 2019

Low aspirin use and high prevalence of pre-eclampsia risk factors among pregnant women in a multinational SLE inception cohort.  78:1010-1012. 2019

Genetic variation at the glycosaminoglycan metabolism pathway contributes to the risk of psoriatic arthritis but not psoriasis.  78:355-364. 2019

Genetic variation at the glycosaminoglycan metabolism pathway contributes to the risk of psoriatic arthritis but not psoriasis.  78:355-364. 2019

Response to: 'Can we prescribe TMP/SMX prophylaxis without any concerns equally for all patients with rheumatic disease?' by Suyama and Okada.  78. 2019

Tapering Janus kinase inhibitors in rheumatoid arthritis with low disease activity or remission: Reality or dream?.  78:153-154. 2019

Comparative risk of serious infections among real-world users of biologics for psoriasis or psoriatic arthritis 2019

Development and initial validation of the MS score for diagnosis of macrophage activation syndrome in systemic juvenile idiopathic arthritis.  78:1357-1362. 2019

Emergent high fatality lung disease in systemic juvenile arthritis.  78:1722-1731. 2019

Neuropsychiatric events in systemic lupus erythematosus: A longitudinal analysis of outcomes in an international inception cohort using a multistate model approach 2019

Remission or low disease activity as a target in systemic lupus erythematosus.  78. 2019

First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus (GLADEL, Grupo Latino Americano de Estudio del Lupus)-Pan-American League of Associations of Rheumatology (PANLAR).  77:1549-1557. 2018

Response to: 'Use of urate-lowering therapies is not associated with an increase in the risk of incident dementia in older adults' by Lee and Song.  77:e74. 2018

Use of urate-lowering therapies is not associated with an increase in the risk of incident dementia in older adults.  77:1243-1245. 2018

Response to: 'A response to singh. “Lesinurad combination therapy with allopurinol in gout: Do CLEAR studies make the treatment of gout clearer?”' by valiyil and schechter.  77. 2018

Risk of malignancy associated with paediatric use of tumour necrosis factor inhibitors.  77:1012-1016. 2018

Prophylactic effect of trimethoprim-sulfamethoxazole for pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoids.  77:644-649. 2018

EULAR gout treatment guidelines by Richette et al.: Uric acid and neurocognition.  77. 2018

Biomarker-related risk for myocardial infarction and serious infections in patients with rheumatoid arthritis: a population-based study.  77:386-392. 2018

Role of serum urate in neurocognitive function and dementia: new evidence contradicts old thinking.  77:317-318. 2018

2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups.  76:1955-1964. 2017

Remission and Low Disease Activity Status (LDAS) protect lupus patients from damage occurrence: data from a multiethnic, multinational Latin American Lupus Cohort (GLADEL).  76:2071-2074. 2017

Weight loss for overweight and obese individuals with gout: A systematic review of longitudinal studies.  76:1870-1882. 2017

Comparative effectiveness of allopurinol versus febuxostat for preventing incident renal disease in older adults: An analysis of Medicare claims data.  76:1669-1678. 2017

Burden of musculoskeletal disorders in the Eastern Mediterranean Region, 1990-2013: Findings from the Global Burden of Disease Study 2013.  76:1365-1373. 2017

Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: Integrated analysis of data from the global clinical trials.  76:1253-1262. 2017

Lesinurad combination therapy with allopurinol in gout: Do CLEAR studies make the treatment of gout clearer?.  76:779-781. 2017

Chasing crystals out of the body: Will treat to serum urate target for gout help us get there?.  76:629-631. 2017

Treat-To-Target (T2T) recommendations for gout.  76:632-638. 2017

Development of a Glucocorticoid Toxicity Index (GTI) using multicriteria decision analysis.  76:543-546. 2017

Allopurinol and the risk of atrial fibrillation in the elderly: A study using medicare data.  76:72-78. 2017

Are allopurinol dose and duration of use nephroprotective in the elderly? A Medicare claims study of allopurinol use and incident renal failure.  76:133-139. 2017

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update.  76:960-977. 2017

Renal dosing of allopurinol results in suboptimal gout care.  76. 2017

Decreased SMG7 expression associates with lupus-risk variants and elevated antinuclear antibody production.  75:2007-2013. 2016

Comparative effects of biologics on cardiovascular risk among older patients with rheumatoid arthritis.  75:1813-1818. 2016

Increased pretreatment serum IFN-β/α ratio predicts non-response to tumour necrosis factor α inhibition in rheumatoid arthritis.  75:1757-1762. 2016

Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis.  75:1843-1847. 2016

Cervical cancer risk with the use of tumour necrosis factor inhibitors in rheumatoid arthritis: To worry or not to worry?.  75:1265-1267. 2016

Tofacitinib, an oral Janus kinase inhibitor: Analysis of malignancies across the rheumatoid arthritis clinical development programme.  75:831-841. 2016

2016 Classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: A European league against Rheumatism/American college of Rheumatology/Paediatric rheumatology international trials organisation collaborative initiative.  75:481-489. 2016

Association of hyperlipidaemia, inflammation and serological status and coronary heart disease among patients with rheumatoid arthritis: Data from the National Veterans Health Administration.  75:341-347. 2016

Preferential association of a functional variant in complement receptor 2 with antibodies to double-stranded DNA.  75:242-252. 2016

Opportunistic infections and biologic therapies in immune-mediated inflammatory diseases: Consensus recommendations for infection reporting during clinical trials and postmarketing surveillance.  74:2107-2116. 2015

2015 Gout classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative.  74:1789-1798. 2015

A deletion at adamts9-magi1 locus is associated with psoriatic arthritis risk.  74:1875-1881. 2015

Factors associated with damage accrual in patients with systemic lupus erythematosus: Results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort.  74:1706-1713. 2015

Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus: Data from an international inception cohort.  74:1530-1536. 2015

Development of EULAR recommendations for the reporting of clinical trial extension studies in rheumatology.  74:963-969. 2015

Discontinuation of tumour necrosis factor inhibitors in patients with rheumatoid arthritis in low-disease activity: Persistent benefits. Data from the Corrona registry.  74:1150-1155. 2015

Risk of hospitalised infection in rheumatoid arthritis patients receiving biologics following a previous infection while on treatment with anti-TNF therapy.  74:1065-1071. 2015

The number of flares patients experience impacts on damage accrual in systemic lupus erythematosus: Data from a multiethnic Latin American cohort.  74:1019-1023. 2015

Sensitivity and sensitisation in relation to pain severity in knee osteoarthritis: Trait or state?.  74:682-688. 2015

When gout goes to the heart: Does gout equal a cardiovascular disease risk factor?.  74:631-634. 2015

The comparative effectiveness of abatacept versus anti-tumour necrosis factor switching for rheumatoid arthritis patients previously treated with an anti-tumour necrosis factor.  74:430-436. 2015

Racial disparities in knee and hip total joint arthroplasty: An 18-year analysis of national medicare data.  73:2107-2115. 2014

Non-viral opportunistic infections in new users of tumour necrosis factor inhibitor therapy: Results of the SAfety assessment of biologic ThERapy (SABER) study.  73:1942-1948. 2014

A case report of progressive multifocal leucoencephalopathy (PML) associated with adalimumab.  73:1429-1430. 2014

Gene-body mass index interactions are associated with methotrexate toxicity in rheumatoid arthritis.  73:785-786. 2014

The association between inflammatory markers, serum lipids and the risk of cardiovascular events in patients with rheumatoid arthritis.  73:1301-1308. 2014

Heart failure risk among patients with rheumatoid arthritis starting a TNF antagonist.  72:1813-1818. 2013

Clinical associations of the metabolic syndrome in systemic lupus erythematosus: Data from an international inception cohort.  72:1308-1314. 2013

Genome-wide association analysis of anti-TNF drug response in patients with rheumatoid arthritis.  72:1375-1381. 2013

Serum urate association with hypertension in young adults: Analysis from the Coronary Artery Risk Development in Young Adults cohort.  72:1321-1327. 2013

Co-localisation of non-cartilaginous articular pathology increases risk of cartilage loss in the tibiofemoral joint - The MOST study.  72:942-948. 2013

Fine mapping of Xq28: Both MECP2 and IRAK1 contribute to risk for systemic lupus erythematosus in multiple ancestral groups.  72:437-444. 2013

Low-dose prednisone chronotherapy for rheumatoid arthritis: A randomised clinical trial (CAPRA-2).  72:204-210. 2013

The role of varus and valgus alignment in the initial development of knee cartilage damage by MRI: The MOST study.  72:235-240. 2013

Mycobacterial diseases and antitumour necrosis factor therapy in USA.  72:37-42. 2013

Breaking the law of valgus: The surprising and unexplained prevalence of medial patellofemoral cartilage damage.  71:1827-1832. 2012

Variation in the ICAM1-ICAM4-ICAM5 locus is associated with systemic lupus erythematosus susceptibility in multiple ancestries.  71:1809-1814. 2012

Seizure disorders in systemic lupus erythematosus results from an international, prospective, inception cohort study.  71:1502-1509. 2012

A role for PACE4 in osteoarthritis pain: Evidence from human genetic association and null mutant phenotype.  71:1042-1048. 2012

Mortality due to coronary heart disease and kidney disease among middle-aged and elderly men and women with gout in the Singapore Chinese Health Study.  71:924-928. 2012

Analysis of autosomal genes reveals gene-sex interactions and higher total genetic risk in men with systemic lupus erythematosus.  71:694-699. 2012

Transancestral mapping of the MHC region in systemic lupus erythematosus identifies new independent and interacting loci at MSH5, HLA-DPB1 and HLA-G.  71:777-784. 2012

IRF5 haplotypes demonstrate diverse serological associations which predict serum interferon alpha activity and explain the majority of the genetic association with systemic lupus erythematosus.  71:463-468. 2012

Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: The ROSE study.  71:198-205. 2012

Predicting low disease activity and remission using early treatment response to antitumour necrosis factor therapy in patients with rheumatoid arthritis: Exploratory analyses from the TEMPO trial.  71:206-212. 2012

Cardiac and thromboembolic complications and mortality in patients undergoing total hip and total knee arthroplasty.  70:2082-2088. 2011

Autoantibodies as biomarkers for the prediction of neuropsychiatric events in systemic lupus erythematosus.  70:1726-1732. 2011

Phenotypic associations of genetic susceptibility loci in systemic lupus erythematosus.  70:1752-1757. 2011

Presence of MRI-detected joint effusion and synovitis increases the risk of cartilage loss in knees without osteoarthritis at 30-month follow-up: The MOST study.  70:1804-1809. 2011

Risk factors for medial meniscal pathology on knee MRI in older US adults: A multicentre prospective cohort study.  70:1733-1739. 2011

The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agents.  70:1401-1406. 2011

Validation of pain and patient global scales in chronic gout: Data from two randomised controlled trials.  70:1277-1281. 2011

SF-36 summary and subscale scores are reliable outcomes of neuropsychiatric events in systemic lupus erythematosus.  70:961-967. 2011

Assessment of synovitis with contrast-enhanced MRI using a whole-joint semiquantitative scoring system in people with, or at high risk of, knee osteoarthritis: The MOST study.  70:805-811. 2011

High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis.  70:785-791. 2011

Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis.  70:576-582. 2011

US patients of hispanic and African ancestry develop lupus nephritis early in the disease course: Data from LUMINA, a multiethnic US cohort (LUMINA LXXIV).  70:393-394. 2011

An assessment of disease flare in patients with systemic lupus erythematosus: A comparison of BILAG 2004 and the flare version of SELENA.  70:54-59. 2011

Explaining the cardiovascular risk associated with rheumatoid arthritis: Traditional risk factors versus markers of rheumatoid arthritis severity.  69:1920-1925. 2010

Serum urate and its relationship with alcoholic beverage intake in men and women: Findings from the Coronary Artery Risk Development in Young Adults (CARDIA) cohort.  69:1965-1970. 2010

Varus and valgus alignment and incident and progressive knee osteoarthritis.  69:1940-1945. 2010

Risk of elevated liver enzymes associated with TNF inhibitor utilisation in patients with rheumatoid arthritis.  69:1612-1617. 2010

From bone biology to clinical outcome: State of the art and future perspectives.  69:1415-1419. 2010

ITGAM coding variant (rs1143679) influences the risk of renal disease, discoid rash and immunological manifestations in patients with systemic lupus erythematosus with European ancestry.  69:1329-1332. 2010

Patient and rheumatologist perspectives on glucocorticoids: An exercise to improve the implementation of the European League Against Rheumatism (EULAR) recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases.  69:1015-1021. 2010

Subchondral bone attrition may be a reflection of compartment-specific mechanical load: The MOST Study.  69:841-844. 2010

Genetic variants of STAT4 associated with rheumatoid arthritis in persons of Asian and European ancestry do not replicate in African Americans.  69:625-626. 2010

The TRAF1-C5 region on chromosome 9q33 is associated with multiple autoimmune diseases.  69:696-699. 2010

Prospective analysis of neuropsychiatric events in an international disease inception cohort of patients with systemic lupus erythematosus.  69:529-535. 2010

Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and/or leflunomide.  69:43-47. 2010

High systemic bone mineral density increases the risk of incident knee OA and joint space narrowing, but not radiographic progression of existing knee OA: The MOST study.  69:163-168. 2010

Meniscal pathology on MRI increases the risk for both incident and enlarging subchondral bone marrow lesions of the knee: The MOST study.  69:1796-1802. 2010

Relation of synovitis to knee pain using contrast-enhanced MRIs.  69:1779-1783. 2010

Use of "spydergrams" to present and interpret SF-36 health-related quality of life data across rheumatic diseases.  68:1800-1804. 2009

Change in MRI-detected subchondral bone marrow lesions is associated with cartilage loss: The MOST Study. A longitudinal multicentre study of knee osteoarthritis.  68:1461-1465. 2009

Opportunities for improving medication use and monitoring in gout.  68:1265-1270. 2009

Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus.  67:1724-1731. 2008

Cigarette smoking, disease severity and autoantibody expression in African Americans with recent-onset rheumatoid arthritis.  67:1529-1534. 2008

Bisphosphonates for osteoarthritis prevention: "Holy Grail" or not?.  67:1358-1359. 2008

Smoking increases peptidylarginine deiminase 2 enzyme expression in human lungs and increases citrullination in BAL cells.  67:1488-1492. 2008

Gout is associated with more comorbidities, poorer health-related quality of life and higher healthcare utilisation in US veterans.  67:1310-1316. 2008

Predictors of premature gonadal failure in patients with systemic lupus erythematosus. Results from LUMINA, a multiethnic US cohort (LUMINA LVIII).  67:1170-1173. 2008

A modified Delphi exercise to determine the extent of consensus with OMERACT outcome domains for studies of acute and chronic gout.  67:888-891. 2008

Seizures in patients with systemic lupus erythematosus: Data from LUMINA, a multiethnic cohort (LUMINA LIV).  67:829-834. 2008

Systemic lupus erythaematosus in a multiethnic US cohort (LUMINA) LIII: Disease expression and outcome in acute onset lupus.  67:500-504. 2008

The relationship between cancer and medication exposures in systemic lupus erythaematosus: A case-cohort study.  67:74-79. 2008

EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases.  66:1560-1567. 2007

Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: Data from LUMINA, a multiethnic US cohort (LUMINA L).  66:1168-1172. 2007

African-American and Hispanic ethnicities, renal involvement and obesity predispose to hypertension in systemic lupus erythematosus: Results from LUMINA, a multiethnic cohort (LUMINAXLV).  66:618-622. 2007

Systemic lupus erythematosus in a multiethnic US cohort LUMINA (XLI): Factors predictive of self-reported work disability.  66:12-17. 2007

Sex differences in gout epidemiology: Evaluation and treatment.  65:1368-1372. 2006

Racial or ethnic differences in allele frequencies of sinqle-nucleotide polymorphisms in the methylenetetrahydrofolate reductase gene and their influence on response to methotrexate in rheumatoid arthritis.  65:1213-1218. 2006

Smoking interacts with genetic risk factors in the development of rheumatoid arthritis among older Caucasian women.  65:1163-1167. 2006

Systemic lupus erythematosus in a multiethnic cohort: LUMINA XXXV. Predictive factors of high disease activity over time.  65:1168-1174. 2006

Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXIV. Cytotoxic treatment is an additional risk factor for the development of symptomatic osteonecrosis in lupus patients: Results of a nested matched case-control study.  65:785-790. 2006

Safety of low dose glucocorticoid treatment in rheumatoid arthritis: Published evidence and prospective trial data.  65:285-293. 2006

Correlation of serum B lymphocyte stimulator and β2 microglobulin with autoantibody secretion and systemic involvement in primary Sjögren's syndrome.  64:1050-1055. 2005

Gout epidemiology: Results from the UK General Practice Research Database, 1990-1999.  64:267-272. 2005

Immunohistochemistry of normal synovium [2] (multiple letters).  63:1532-1533. 2004

Immunohistochemistry of normal human knee synovium: A quantitative study.  63:785-790. 2004

Increased DNA fragmentation and ultrastructural changes in fibromyalgic muscle fibres.  63:245-251. 2004

Glucocorticoids in the treatment of early and late RA.  62:1033-1037. 2003

Polymicrobial septic arthritis in a patient with Wilson's disease [12].  62:693-694. 2003

The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjögren's syndrome.  62:168-171. 2003

Mortality risk associated with rheumatoid arthritis in a prospective cohort of older women: Results from the Iowa Women's Health Study.  61:994-999. 2002

Cigarette smoking and rheumatoid arthritis severity.  56:463-469. 1997

Rheumatoid arthritis preceding the onset of polyarticular tophaceous gout..  55:489-490. 1996

Survival and drug discontinuation analyses in a large cohort of methotrexate treated rheumatoid arthritis patients.  54:708-712. 1995

Folate supplementation and methotrexate [3].  52:315-316. 1993

Molecular and cellular mechanisms of joint destruction in rheumatoid arthritis: Two cellular mechanisms explain joint destruction?.  52. 1993

Controlled trial of methotrexate versus 10-deazaaminopterin in the treatment of rheumatoid arthritis.  51:600-603. 1992

False positive results for antibody to HIV in two men with systemic lupus erythematosus.  51:1071-1073. 1992

Local immune responses in certain extra-articular manifestations of rheumatoid arthritis.  51:698-701. 1992

5-Fluorouracil in the treatment of scleroderma: A randomised, double blind, placebo controlled international collaborative study.  49:926-928. 1990

Osteoarthritis: Definitions and criteria.  49:201. 1990

Auricular chondritis and diffuse proliferative glomerulonephritis in primary Sjögren's syndrome.  48:683-685. 1989

Pulmonary hypertension in primary Sjogren's syndrome.  47:251-253. 1988

Sarcoidosis presenting as antinuclear antibody positive glomerulonephritis.  47:337-339. 1988

Brucellar arthritis: A study of 39 Peruvian families.  46:506-509. 1987

A new promising treatment in systemic sclerosis: 5-fluorouracil.  46:763-767. 1987

Rheumatic manifestations of brucellosis..  45:526. 1986

Tissue typing in brucellosis..  45:351. 1986

Multiple microcrystal deposition disease in a patient with systemic lupus erythematosus.  43:498-502. 1984